How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its ...

AI tool adoption is high and continues to climb. The survey shows most developers are now using AI assistants in their workflow or plan to soon, with daily and weekly use becoming routine. Trust is ...

Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in ...

RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.02 since the market last closed. This is a 0.45 ...

Fluidstack, a startup that builds specialized data centers for AI companies, is in talks to raise a $1 billion round at an $18 billion valuation, potentially led by Jane Street, Bloomberg reports.

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. David Kindness is a Certified Public Accountant (CPA) and an expert ...

A good sum of two good parts. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market cycle on a ...

Rich with history and just a short drive away from iconic landmarks of the West—namely Grand Teton National Park and Yellowstone—Jackson Hole, Wyoming, is a beloved American destination for a myriad ...